Modern possibilities for preventing the formation of liver fibrosis in children: the basics of preventive pediatric hepatology
https://doi.org/10.31146/1682-8658-ecg-215-7-107-118
Abstract
Liver fibrosis is a natural outcome of almost any liver disease with a steady increase in incidence throughout the world. Considering the pathogenesis of liver fibrosis, the doctor-researcher is faced with the fact that the balance of regeneration processes in relation to the process of chronic inflammation is disturbed. The extracellular matrix accumulates in the liver tissue. Although this is a genetically determined process, but modifying factors play an important role in the progression of the disease. Liver fibrosis in its dynamic development leads to liver cirrhosis, hepatocellular carcinoma. Current data indicate the possibility of reversibility of liver fibrosis at any stage. Understanding the molecular mechanisms of the development of the pathological process is a key area of work for scientists involved in the development of antifibrotic therapy. The article discusses modern views on the prevention of the disease and the prospects for influencing the processes of liver fibrosis with an emphasis on childhood.
About the Authors
K. I. Grigoryev
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
L. A. Kharitonova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
References
1. Wells R. G. Hepatic Fibrosis in Children and Adults. Clin Liver Dis (Hoboken). 2017 Apr; 9(4): 99-101. Published online. 2017 Apr 20. doi: 10.1002/cld.623.
2. Mack C. L. What causes biliary atresia? Unique aspects of the neonatal immune system provide clues to disease pathogenesis. Cell Mol Gastroenterol Hepatol. 2015; vol.1, Issue 3:267-274. doi: 10.1016/j.jcmgh.2015.04.001.
3. Surkov A. Modern Diagnostic Tools for Detecting Hepatic Fibrosis in Children. Pediatric pharmacology. 2009;6(3):45-51(In Russ.)@@ Сурков А. Н. Методы диагностики фиброза и цирроза печени у детей. Вопросы диагностики в педиатрии 2011; 3(4): 5-14.
4. Tsukanov V. V., Yurkina A. S., Ushakova T. A., Blinov D. V. Epidemiological features of non-alcoholic fatty liver disease in Novosibirsk (Siberian Federal District): regional data from an open multicenter prospective study DIREG 2. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2016; 2:17-27. (In Russ.)@@ Цуканов В. В., Юркина А. С., Ушакова Т. А., Блинов Д. В. Эпидемиологические особенности неалкогольной жировой болезни печени в Новосибирске (Сибирский федеральный округ): региональные данные открытого многоцентрового проспективного исследования DIREG 2. Современная фармакоэкономика и фармакоэпидемиология. 2016; 2: 17-27.
5. Anstee Q. M., Darlay R., Cockell S., Meroni M., Govaere O., Tiniakos D., Burt A. D., Bedossa P., Palmer J., et al. Genome-wide Association Study of Non-alcoholic Fatty Liver and Steatohepatitis in a Histologically Characterised Cohort. J. Hepatol. 2020; 73 (3), 505-515. doi: 10.1016/j.jhep.2020.04.003.
6. Dong X.C. PNPLA3-A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease. Front. Med. 2019; 6: 304. doi: 10.3389/fmed.2019.00304.
7. Lee Y.A, Wallace M.C, Friedman S. L. Pathobiology of liver fibrosis: a translational success story. Gut. 2015; 64: 830-41. doi: 10.1136/gutjnl-2014-306842.
8. Volynets G. V., Nikitin A. V. Pathophysiological aspects of liver damage in children with alpha-1-antitrypsin deficiency. Ros Vestn Perinatol i Pediatr. 2020; 65:(1): 11-21. (in Russ.) doi: 10.21508/1027-4065-2020-65-1-11-21.@@ Волынец Г. В., Никитин А. В. Патофизиологические аспекты поражения печени у детей при недостаточности альфа-1-антитрипсина. Рос вестн перинатол и педиатр 2020; 65:(1): 11-21. doi: 10.21508/1027-4065-2020-65-1-11-21.
9. Manmadhan S., Ehmer U. Hippo Signaling in the Liver - A Long and Ever-Expanding Story. Front. Cel Dev. Biol. 2019; (7): 33-37. doi: 10.3389/fcell.2019.00033.
10. Hughes C.E., Nibbs R. J. B. A Guide to Chemokines and Their Receptors. FEBS J. 2018; 285 (16), 2944-2971. doi:10.1111/febs.14466.
11. Zhang W., Conway S. J., Liu Y. at al. Heterogeneity of Hepatic Stellate Cells in Fibrogenesis of the Liver: Insights from Single-Cell Transcriptomic Analysis in Liver Injury. Cells. 2021 Aug 19; 10(8):2129. doi: 10.3390/cells10082129.
12. Liangpunsakul S., Chalasani N. Lipid Mediators of Liver Injury in Nonalcoholic Fatty Liver Disease. Am. J. Physiol.-Gastrointestinal Liver Physiol. 2019; 316 (1), G75-G81. doi:10.1152/ajpgi.00170.2018.
13. Mannaerts I., Thoen L. F.R., Eysackers N. et al. Unfolded Protein Response Is an Early, Non-critical Event during Hepatic Stellate Cell Activation. Cell Death Dis. 2019; 10 (2), 98. doi:10.1038/s41419-019-1327-5.
14. Acharya P., Chouhan K., Weiskirchen S., Weiskirchen R. Cellular Mechanisms of Liver Fibrosis. Front. Pharmacol. 2021; 12:671640. doi: 10.3389/fphar.2021.671640.
15. Kisseleva T. The Origin of Fibrogenic Myofibroblasts in Fibrotic Liver. Hepatology. 2017; 65 (3), 1039-1043. doi:10.1002/hep.28948.
16. Рediatric hepatology. Ed. B. S. Kaganov. Moscow. Dynasty, 2009, 576 p. (In Russ.)@@ Детская гепатология. Под ред. Б. С. Каганова. М.: Династия, 2009: 576 с.
17. Isakov V. A. How to determine the severity of liver fibrosis and why? Klinicheskaya gastroenterologiya i gepatologiya. 2008; 1(2):72-75. (In Russ.)@@ Исаков В. А. Как определять выраженность фиброза печени и зачем? Клиническая гастроэнтерология и гепатология. 2008; 1 (2):72-75.
18. Surkov A. N., Namazova-Baranova L.S., Vashakmadze N. D. et al. Transient elastography is a non-invasive method for diagnosing the stages of liver fibrosis in children with rare diseases. Sovremennyye tekhnologii v meditsine. 2016; Vol. 8, № 3: 56-63. (In Russ.)@@ Сурков А. Н., Намазова-Баранова Л.С., Вашакмадзе Н. Д., Геворкян А. К., Томилова А. Ю., Потапов А. С., Симонова О. И., Кузенкова Л. М., Баранов А. А. Транзиентная эластография - неинвазивный метод диагностики стадий фиброза печени у детей с редкими болезнями. Современные технологии в медицине. 2016; Том 8, № 3: 56-63.
19. Kulebina E. A., Surkov A. N. Mechanisms of liver fibrosis formation: current concepts. Pediatriya. 2019; 98(6): 166-170. (In Russ.) doi: 10.24110/0031-403X-2019-98-6-166-170.@@ Кулебина Е. А., Сурков А. Н. Механизмы формирования фиброза печени: современные представления. Педиатрия. 2019; 98, № 6: 166-170. doi.org/10.24110/0031-403X-2019-98-6-166-170.
20. Poteshkina N. G., Adzhigaitkanova S. K. Modern principles of diagnosis and treatment of complications of liver cirrhosis: teaching aid. Moscow. RNIMU im. N. I. Pirogova, 2013, 44 p. (in Russ.)@@ Потешкина Н. Г., Аджигайтканова С. К. Современные принципы диагностики и лечения осложнений цирроза печени: учебно-методическое пособие. - М., РНИМУ им. Н. И. Пирогова, 2013: 44 с.
21. Staufer K. Current Treatment Options for Cystic Fibrosis-Related Liver Disease. 2020; Ijms 21 (22), 8586. doi: 10.3390/ijms21228586. (In Russ.)
22. Dunn R., Wetten A., McPherson S., Donnelly M. C. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol. 2022 Jan 7;28(1):76-95. doi: 10.3748/wjg.v28.i1.76.
23. Strokova T. V., Surkov A. G., Bagaeva M. E., Zubovich A. I., Pavlovskaya E. V., Matinyan I. A. Variants of autoimmune hepatitis manifestation in children. Pediatria n. a. G. N. Speransky. 2018; 97 (6): 8-13. (In Rus.)@@ Строкова Т. В., Сурков А. Г., Багаева М. Э., Зубович А. И., Павловская Е. В., Матинян И. А. Варианты манифестации аутоиммунного гепатита у детей. Педиатрия им. Г. Н. Сперанского. 2018; 97(6): 8-13.
24. Yagoda A. V., Koroy P. V., Slyadnev S. A., Kravchenko Yu. A. Therapy of non-alcoholic fatty liver disease: relationship with soluble adhesion molecules. Therapy. 2020;(4): 110-116. (in Russ.) doi: 10.18565/therapy.2020.4.110-116.@@ Ягода А. В., Корой П. В., Сляднев С. А., Кравченко Ю. А. Терапия неалкогольной жировой болезни печени: взаимосвязь с растворимыми молекулами адгезии. Терапия. 2020; № 4: 110-116. doi: 10.18565/therapy.2020.4.110-116.
25. Peng X., Yang Y., Tang L., Wan J., Dai J., Li L., Huang J. et al. Therapeutic Benefits of Apocynin in Mice with lipopolysaccharide/D-Galactosamine-Induced Acute Liver Injury via Suppression of the Late-Stage Pro-apoptotic AMPK/JNK Pathway. Biomed. Pharmacother. 2020;125:110020. doi: 10.1016/j.biopha.2020.110020.
26. Weiskirchen R., Weiskirchen S., Tacke F. Recent Advances in Understanding Liver Fibrosis: Bridging Basic Science and Individualized Treatment Concepts. 2018; F1000Res 7, F1000. doi: 10.12688/f1000research.14841.1.
27. Tang P.C., Zhang Y. Y., Li J. S. et al. LncRNA-Dependent Mechanisms of Transforming Growth Factor-β: From Tissue Fibrosis to Cancer Progression. Noncoding RNA. 2022 May 25;8(3):36. doi: 10.3390/ncrna8030036.
28. Ambade A., Lowe P., Kodys K., Catalano D., Gyongyosi B., Cho Y., et al. Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice. Hepatology. 2019; 69 (3): 1105-21. doi: 10.1002/hep.30249.
29. Khurana A., Sayed N., Allawadhi P., Weiskirchen R. It’s All about the Spaces between Cells: Role of Extracellular Matrix in Liver Fibrosis. Ann. Transl Med. 2021; 11: 39-40. doi: 10.21037/atm-20-2948.
30. Levada K., Omelyanchik A., Rodionova V., Weiskirchen R., Bartneck M. Magnetic-assisted Treatment of Liver Fibrosis. Cells 2019; 8 (10): 1279. doi: 10.3390/cells8101279.
31. Kanmani P., Kim H. Probiotics counteract the expression of hepatic profibrotic genes via the attenuation of TGF-β/SMAD signaling and autophagy in hepatic stellate cells. PLoS One. 2022; 17: e0262767. doi: 10.1371/journal.pone.0262767.
32. Ohashi T., Yamamoto T. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin. Exp. Dermatol. 2015; 24: 698-702. doi: 10.1111/exd.12752.
33. Lu Q., Zhou Y., Xu M., Liang X., Jing H., Wang X., Li N. Sequential delivery for hepatic fibrosis treatment based on carvedilol loaded star-like nanozyme. J Control Release. 2021; 341:247-60. doi: 10.1016/j.jconrel.2021.11.033.
34. Evseenko D. A., Dundarov Z. A., Nadyrov E. A., Maiorov V. M.Comprehensive evaluation of the effectiveness of antioxidant therapy in patients with acute bleeding on the background of liver cirrhosis. Gepatologiya i gastroenterologiya. 2020; 4(1): 68-75. (in Russ.) doi: 10.25298/2616-5546-2020-4-1-68-75.@@ Евсеенко Д. А., Дундаров З. А., Надыров Э. А., Майоров В. М. Комплексная оценка эффективности антиоксидантной терапии у пациентов с острым кровотечением на фоне цирроза печени. Гепатология и гастроэнтерология. 2020; Т. 4, № 1: 68-75. doi: 10.25298/2616-5546-2020-4-1-68-75.
35. Xu F., Tautenhahn H. M., Dirsch O., Dahmen U. Modulation of Autophagy: A Novel «Rejuvenation» Strategy for the Aging Liver. Oxid Med Cell Longev. 2021; 2021:6611126. doi: 10.1155/2021/6611126.
Review
For citations:
Grigoryev K.I., Kharitonova L.A. Modern possibilities for preventing the formation of liver fibrosis in children: the basics of preventive pediatric hepatology. Experimental and Clinical Gastroenterology. 2023;(7):107-118. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-215-7-107-118
Views:
135
Email this article 